September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Outer retinal reflectivity on En-face OCT as a new tool to detect early stage hydroxychloroquine maculopathy.
Author Affiliations & Notes
  • Adrien Viotte
    ophtalmology, CHU Besançon, Besançon, France
  • Guillaume Bigan
    ophtalmology, CHU Besançon, Besançon, France
  • Mathieu Flores
    ophtalmology, CHU Besançon, Besançon, France
  • Caroline Girard
    ophtalmology, CHU Besançon, Besançon, France
  • Bernard Y Delbosc
    ophtalmology, CHU Besançon, Besançon, France
  • Maher Saleh
    ophtalmology, CHU Besançon, Besançon, France
  • Footnotes
    Commercial Relationships   Adrien Viotte, None; Guillaume Bigan, None; Mathieu Flores, None; Caroline Girard, None; Bernard Delbosc, None; Maher Saleh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4247. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Adrien Viotte, Guillaume Bigan, Mathieu Flores, Caroline Girard, Bernard Y Delbosc, Maher Saleh; Outer retinal reflectivity on En-face OCT as a new tool to detect early stage hydroxychloroquine maculopathy.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4247.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Hydroxychloroquine (HCQ) maculopathy can cause irreversible vision loss. Alteration of the parafoveal photoreceptors has been reported to be one of the earliest histopathological sign. The relationship between the ellipsoid zone reflectivity and cone density was recently demonstrated. The main objective of the study was to measure the outer retinal reflectivity in patients taking a HCQ regimen without proven toxicity on routine screening tests. The second objective was to investigate the relationship between the reflectivity measured and the screening tests outcomes.

Methods : Consecutive patients visiting for HCQ toxicity screening in the Ophthalmology Department of the Besançon University Hospital (France) were included. All patients underwent a complete ophthalmic examination with a ten-degrees automated perimetry (with measurement of the foveal threshold and the mean 2-5 degrees), fundus autofluorescence, multifocal electroretinogram (with measurement of N1, P1 and N2 amplitudes in a 2-5° range) and spectral-domain optical coherence tomography with en-face reconstruction of the ellipsoid zone and the retinal pigment epithelium (with measurement of the absolute reflectivity expressed in greyscale in the 2-5° range).

Results : Thirty-nine patients (76 eyes) were studied. None of them displayed a toxic maculopathy. The cumulative dose for HCQ ranged from 24 to 2400g (mean ±SD: 706g±620). Bivariate analysis showed a decreased in ellipsoid reflectivity with escalating cumulative doses of HCQ (linear regression, p<0.0001, r2 : 0,3). Reflectivity was also correlated with N1, P1 and N2 amplitudes (p<0.05). Finally, reflectivity was statistically correlated with 5 degrees threshold perimetry. (p<0.005).

Conclusions : Parafoveolar ellipsoid reflectivity with en face OCT could be a rapid biomarker, repeatable and quantifiable to screen HCQ maculopathy at an early stage, a preclinical stage.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×